Stay up-to-date with our latest news, blog articles, videos, and event announcements. Learn from business success stories and gain access to valuable e-books and resources.
Sterile fill-finish capacity is one of the most critical outsourcing decisions in injectable drug development. For pharmaceutical and biotech companies, the challenge is not only to find a contract manufacturer able to fill a Phase I clinical batch. The real […]
Adragos Pharma is pleased to confirm its participation in the 14th Antibody Industrial Symposium (AIS2026), taking place in Montpellier, France. Organised by MabDesign and MabImprove, AIS2026 brings together leading players across the antibody and biologics value chain — from discovery […]
Outsourcing commercial manufacturing is never only a capacity decision. For creams, gels, ointments and non-sterile liquids, it is a quality, supply continuity and patient safety decision. A sponsor can transfer a formula, a method and a target batch size. What […]
Selecting a CDMO for high-potency active pharmaceutical ingredient development requires more than checking whether a partner “handles HPAPIs”. Pharma and biotech teams need to understand whether the CDMO can combine formulation expertise, proven containment, analytical development, GMP manufacturing, cleaning validation […]
Adragos Pharma is pleased to announce its participation in Biotech Outsourcing Strategies (BOS) Basel 2026, taking place in Basel, Switzerland, from June 30 to July 1. As a global Contract Development and Manufacturing Organisation (CDMO), we look forward to connecting […]
Selecting a Contract Development and Manufacturing Organisation (CDMO) for high-potency active pharmaceutical ingredient (HPAPI) small molecule formulation development requires a verification process that is fundamentally more rigorous than for standard compound programmes. The containment infrastructure, operator safety controls and Good […]
Get notified on our latest news.
